Opthea Limited (OPT) Return on Assets ROA from the fourth quarter of 2025 to fourth quarter of 2024 and for the year 2025, Average High and Low, Fundamental Ratios from Jun 30 2025 to Jun 30 2024 - CSIMarket
Opthea Limited's ROA from the fourth quarter of 2025 to the fourth quarter of 2024 and 5 Year Period
Return on Assets, Quarterly Results, Trends, Rankings, Statistics
What is Opthea Limited's ROA in the fourth quarter of 2025?
Opthea Limited recorded a cumulative net loss of $-163 million during 12 months ending in the fourth quarter of 2025, resulting in a negative return on assets (ROA) of -286.61%.
However, within the Healthcare sector 930 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the third quarter of 2025 from to 4741.
In a transformative era for retinal disease treatment, Opthea Limited is emerging as a beacon of hope for patients suffering from wet age-related macular degeneration (wet AMD). As the company prepares for critical Phase 3 data readouts slated for 2025, it has strategically appointed Parisa Zamiri, MD, PhD, as Chief Medical Officer and Tom Reilly as Chief Financial Officer. These new leadership appointments underscore Opthea s commitment to catalyzing progress in the development of innovative therapies aimed at enhancing patient outcomes.The significance of Opthea s initiatives comes into sharper focus as the company gears up to participate in the 24th EURETINA Congress, set to unfold from September 18 to 22, 2024, in the dynamic city of Barcelona, Spain. The event is a prominent gathering for experts in retinal health, offering a platform for groundbreaking scientific discussions and educational symposiums.
Opthea, a leading biotechnology company focused on developing treatments for retinal and ophthalmology diseases, recently appointed John Han, PharmD, as the Vice President of Medical Affairs. Han brings with him extensive experience in the field, which will be instrumental in furthering Opthea s mission of developing innovative therapies for patients suffering from these conditions. With his appointment, Han will assume a pivotal role in Opthea s medical affairs department, overseeing clinical research, regulatory affairs, and medical communications. His diverse background in pharmaceuticals and healthcare will play a vital role in supporting Opthea s strategic development and commercialization efforts.
The global biopharmaceutical company Opthea Limited has recently announced the appointment of Dr. Arshad M. Khanani, a distinguished retina expert, as their Chief Medical Advisor. This strategic move aims to strengthen Opthea s development and launch preparations for their groundbreaking drug, sozinibercept. Sozinibercept, a potential game-changer in the field of retinal diseases, holds great promise for the millions of people around the world suffering from conditions such as age-related macular degeneration (AMD) and diabetic macular edema (DME). Dr. Khanani s extensive knowledge and experience in the field will prove invaluable in advancing the drug s development and ensuring its successful entry into the market.
Opthea Strengthens Team to Combat Financial Challenges In a strategic move to navigate through financial difficulties, Opthea Limited has recently announced the appointment of two key executives, Dr. Julie Clark as Senior Vice President of Clinical Development, and Dr. Fang Li as Senior Vice President of Regulatory Affairs. Both experts are expected to join the company on February 1st, bringing with them a wealth of experience in developing innovative products for retinal and ophthalmology diseases. Opthea s financial position has been concerning, with a cumulative net loss of $143 million reported for the 12-month period ending in the fourth quarter of 2023. This resulted in a negative return on assets (ROA) of -144.48%, highlighting the company s struggle to generate profits from its assets.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
